leiomyosarcoma (Cancer)
Information
- Disease name
- leiomyosarcoma
- Disease ID
- DOID:1967
- Description
- "A smooth muscle cancer that can arise almost anywhere in the body, but is most common in the uterus, abdomen, or pelvis." [url:http\://www.cancer.gov/dictionary/?CdrID=46027]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04811196 | Active, not recruiting | Phase 1 | A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients | March 29, 2021 | February 2025 |
| NCT04624178 | Active, not recruiting | Phase 2 | A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma | November 5, 2020 | November 5, 2024 |
| NCT01956084 | Active, not recruiting | Phase 1 | Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma | November 2013 | November 2025 |
| NCT02923778 | Active, not recruiting | Phase 2 | Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery | December 31, 2019 | December 1, 2024 |
| NCT04420975 | Active, not recruiting | Phase 1 | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | October 29, 2020 | January 31, 2026 |
| NCT04242238 | Active, not recruiting | Phase 1 | Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas | January 22, 2020 | January 22, 2025 |
| NCT03016819 | Active, not recruiting | Phase 3 | Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) | August 15, 2017 | June 2025 |
| NCT02180867 | Active, not recruiting | Phase 2/Phase 3 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | July 11, 2014 | December 22, 2024 |
| NCT03899805 | Active, not recruiting | Phase 2 | A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas | May 13, 2019 | August 1, 2025 |
| NCT03851614 | Active, not recruiting | Phase 2 | Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors | April 8, 2019 | January 1, 2025 |
| NCT05269355 | Active, not recruiting | Phase 2/Phase 3 | A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) | May 23, 2022 | June 30, 2024 |
| NCT03526679 | Active, not recruiting | Phase 1/Phase 2 | Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma | July 12, 2018 | June 30, 2023 |
| NCT00887809 | Completed | Phase 2 | Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes | April 2009 | November 2014 |
| NCT01426633 | Completed | Phase 1 | Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas | November 2011 | December 2014 |
| NCT01442662 | Completed | Phase 2 | Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine | September 2011 | May 28, 2019 |
| NCT03718091 | Completed | Phase 2 | M6620 (VX-970) in Selected Solid Tumors | January 8, 2019 | July 8, 2020 |
| NCT02247544 | Completed | Phase 2 | Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma | March 2014 | March 12, 2019 |
| NCT02249702 | Completed | Phase 2 | Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma | April 2010 | April 30, 2017 |
| NCT02584309 | Completed | Phase 2 | Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | February 22, 2016 | July 17, 2022 |
| NCT03241745 | Completed | Phase 2 | A Study of Nivolumab in Selected Uterine Cancer Patients | August 3, 2017 | April 1, 2024 |
| NCT03761095 | Completed | Phase 1 | A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS) | March 13, 2019 | February 5, 2024 |
| NCT01447056 | Completed | Phase 1 | Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases | February 2012 | January 22, 2020 |
| NCT00062868 | Completed | Phase 1 | LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma | September 2003 | April 2020 |
| NCT00093080 | Completed | Phase 2 | Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) | October 2004 | November 2008 |
| NCT00282087 | Completed | Phase 2 | Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma | January 2006 | January 2012 |
| NCT00356031 | Completed | Phase 2 | Bevacizumab and Radiation Therapy for Sarcomas | July 2006 | March 2010 |
| NCT00400569 | Completed | Phase 2 | Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma | November 2006 | December 2011 |
| NCT00060944 | Completed | Phase 2 | A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer | May 2003 | May 2008 |
| NCT00503295 | Completed | Phase 2 | Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung | June 2007 | April 2011 |
| NCT00668148 | Completed | Phase 2 | A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma | July 2008 | February 2012 |
| NCT00815945 | Completed | Phase 2 | Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors | June 2008 | January 2012 |
| NCT00837148 | Completed | Phase 2 | Sorafenib and Dacarbazine in Soft Tissue Sarcoma | February 2009 | November 2013 |
| NCT00856050 | Completed | Phase 2 | Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma | February 2009 | March 2014 |
| NCT06308419 | Not yet recruiting | Phase 1 | A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions | July 31, 2024 | February 1, 2031 |
| NCT05548179 | Not yet recruiting | Exploring Clinical Trial Experiences of People With Leiomyosarcoma | October 2023 | October 2025 | |
| NCT06277154 | Not yet recruiting | Phase 2 | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | February 2024 | February 2027 |
| NCT05653388 | Recruiting | Metastatic Leiomyosarcoma Biomarker Protocol | December 22, 2022 | December 2026 | |
| NCT04031677 | Recruiting | Phase 3 | Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma | January 20, 2021 | April 21, 2028 |
| NCT04055220 | Recruiting | N/A | Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas | March 3, 2020 | October 1, 2026 |
| NCT04535271 | Recruiting | Phase 2 | Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma | September 9, 2021 | December 30, 2024 |
| NCT04554914 | Recruiting | Phase 2 | A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases | July 14, 2021 | May 2029 |
| NCT02275286 | Recruiting | Phase 1/Phase 2 | Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients | November 2014 | June 2028 |
| NCT01793168 | Recruiting | Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford | July 2010 | December 2100 | |
| NCT03420014 | Recruiting | Phase 2 | Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA) | December 27, 2018 | December 2025 |
| NCT04925089 | Recruiting | Localized Leiomyosarcoma Biomarker Protocol | April 26, 2023 | April 2025 | |
| NCT05080790 | Recruiting | Phase 2 | Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma | November 15, 2021 | July 26, 2024 |
| NCT05094804 | Recruiting | Phase 1/Phase 2 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | September 9, 2021 | August 15, 2024 |
| NCT05427461 | Recruiting | N/A | Circulating " Cancer Cells / Macrophage " HYbrid Cells in Patients With Sarcoma, Part 2 | January 13, 2023 | July 2026 |
| NCT06299163 | Recruiting | Phase 1 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | May 1, 2024 | December 31, 2027 |
| NCT06088290 | Recruiting | Phase 2/Phase 3 | Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma | September 21, 2023 | November 26, 2026 |
| NCT00414076 | Terminated | Phase 2 | Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma | December 19, 2006 | July 13, 2017 |
| NCT05116683 | Terminated | Phase 2 | ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma | January 11, 2022 | October 27, 2022 |
| NCT04099277 | Terminated | Phase 1 | A Study of LY3435151 in Participants With Solid Tumors | October 28, 2019 | March 5, 2020 |
| NCT02940041 | Terminated | Concordance Between Sonography Amd MRI for Presurgical Diagnosis of Uterine Mesenchymal Malignant Tumors | September 2016 | September 2021 | |
| NCT03959033 | Terminated | Patient Reported Outcome Measures (PROMs) With Trabectedin | November 29, 2016 | August 28, 2019 | |
| NCT04996004 | Terminated | Phase 2 | A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma | June 22, 2021 | December 7, 2023 |
| NCT03509207 | Terminated | Phase 2 | Vorinostat (SAHA) in Uterine Sarcoma | December 14, 2017 | February 4, 2019 |
| NCT01418001 | Terminated | Phase 1/Phase 2 | Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) | August 2011 | November 2015 |
| NCT03651375 | Unknown status | Phase 2 | Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall | February 11, 2017 | March 2022 |
| NCT05204524 | Unknown status | N/A | Temozolomide for Injection Combined With Epirubicin in First-line Treatment of Leiomyosarcoma | August 27, 2021 | August 27, 2023 |
| NCT03989596 | Unknown status | Phase 2 | Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas | June 1, 2018 | December 31, 2022 |
| NCT04214457 | Unknown status | Development of a Predictive Model for Early Differential Diagnosis of Uterine Leiomyomas and Leiomyosarcomas | September 20, 2019 | July 2022 | |
| NCT02983539 | Unknown status | Detection of Circulating Tumor Cells in Patients With Sarcomas | October 2015 | June 2018 | |
| NCT04906876 | Withdrawn | Phase 2 | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas | September 2021 | July 2025 |
| NCT03437070 | Withdrawn | Phase 1 | Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma | June 2019 | June 2023 |
| NCT03773510 | Withdrawn | Phase 3 | Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin | February 28, 2019 | October 1, 2025 |
| NCT05116800 | Withdrawn | Phase 2 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | March 1, 2022 | August 2030 |
- Disase is a (Disease Ontology)
- DOID:4230
- Cross Reference ID (Disease Ontology)
- GARD:6880
- Cross Reference ID (Disease Ontology)
- ICDO:8890/3
- Cross Reference ID (Disease Ontology)
- MESH:D007890
- Cross Reference ID (Disease Ontology)
- NCI:C3158
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:443719001
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0023269
- Exact Synonym (Disease Ontology)
- Leiomyosarcomas
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0100243
- MeSH unique ID (MeSH (Medical Subject Headings))
- D007890